Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Lyn

  • Sai Kundur
  • Hung Nguyen
  • Lloyd McKee
  • Clairissa Cruz
  • Ponniah Selvakumar
  • Ashakumary Lakshmikuttyamma
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101499

Synonyms

Historical Background

Tyrosine kinases play a significant role in different cellular processes such as cell growth, apoptosis, and migration (Ingley 2012; Manning et al. 2002). Also tyrosine kinases regulate many inflammatory modulators that regulate immune response (Ingley 2012; Manning et al. 2002). Src family kinases (SFKs) include different tyrosine kinases like Src, Lyn, Yes, Fyn, Blk, Yrk, Fgr, Hck, and Lck. These intracellular membrane-associated non-receptor tyrosine kinases control different biological processes (Ingley et al. 2007; Parsons and Parsons 2004). The overexpression and higher activity of SFKs enhance different types of cancer cell growth, and various studies demonstrated the involvement of SFKs in various tumor progression and metastasis (Resh 1999; Boggon and Eck 2004; Selvakumar et al. 2007). Lyn is a member of the SFK family; solid tumors including colon cancer, prostate cancer, glioblastoma, and breast cancer exhibit higher Lyn expression (Sun et al. 1998, 2002). Various reports provide the evidence on the role of Lyn in the cancer progression and to consider Lyn as a therapeutic target in preventing solid tumor progression and metastasis (Resh 1999; Boggon and Eck 2004; Selvakumar et al. 2007).

Structure of Lyn

The structure of Lyn contains an N-terminal region encoding a myristoylation site and may contain a palmitoylation site, protein interaction domains (SH3 and SH2), and a kinase domain (SH1) (Boggon and Eck 2004). Lyn exists in two splice variants, designated as Lyn-A (p56) and Lyn-B (p53) isoforms, differed in the SH4 domain (Hibbs et al. 1995; Yi et al. 1991). The reversible N-terminal lipid modification (palmitoylation) and isoform-specific pY32 motif potentially complicate understanding Lyn’s function through their latent ability to regulate activity, interactions, and subcellular localization.

Lyn is regulated by protein interactions through its SH2/SH3 domains as well as via phosphorylation status (Koch et al. 1991). In its inactive state, Lyn is phosphorylated at its carboxyl terminus by C-terminal Src kinase (Csk) creating a binding site for its own SH2 domain. Lyn’s SH3 domain can bind an intramolecular proline motif situated between the SH2 and kinase domains (hinge region), helping generate a stabilized inactive kinase confirmation. Activation of Lyn involves dephosphorylation of the C-terminal tyrosine (Y508) by phosphatases such as CD45 (Wang et al. 2002) and SHP-2 (Futami et al. 2011), as well as through interactions with SH2 and/or SH3 domain-binding motifs, which compete with Lyn’s own SH3/SH2 intramolecular interaction sites, thus releasing the auto-inhibitory configuration of the kinase domain.

Breast Cancer

Lyn was expressed in 14% of various types of breast cancer. Lyn was expressed at higher levels in the invasive, mesenchymal breast cancer lines and higher levels in basal-like breast cancer lines (Choi et al. 2010; Finn et al. 2007; Huang et al. 2007). Knockdown of Lyn in mesenchymal breast cancer lines inhibited invasion. Further, knockdown of Lyn also led to reduced vimentin and N-cadherin and EMT markers but not increased E-cadherin, suggesting that Lyn directs only a portion of the mesenchymal phenotype. It has been reported that Lyn is a mediator of invasion and a possible new therapeutic target to clinically aggressive basal-like breast cancer (Choi et al. 2010).

Lyn was reported to be highly expressed in various types of breast cancer; specifically, Lyn is highly active in the invasive, mesenchymal phenotype and basal-like breast cancer (Choi et al. 2010; Finn et al. 2007; Huang et al. 2007). Lyn silencing led to downregulation of EMT markers such as vimentin and N-cadherin and alteration of mesenchymal phenotype. It has been reported that Lyn is a mediator of invasion and a possible new therapeutic target to clinically aggressive breast cancer (Choi et al. 2010). Recent studies reported Lyn is significantly highly expressed in triple-negative breast cancer (TNBC) cell lines; Lyn knockdown significantly inhibited the TNBC cell migration (Pénzes et al. 2014). Reduced Lyn levels alter claudin-2 expression; bafetinib (INNO-406), a Lyn-selective kinase inhibitor, decreases claudin-2 expression and reduces breast cancer liver metastasis (Tabariès et al. 2015). Knockdown of Lyn and the migration-related CRK-associated substrate (p130Cas) had a significant inhibitory effect on cell migration. The overexpression of mutated Lyn inhibits the anticancer activity of estrogen receptor (Schwarz et al. 2014). Lyn mediates the oncogenic effect of EGFR, the EGFR phosphorylated Lyn (Y32) phosphorylates MCM7, and that regulates DNA replication in breast cancer (Huang et al. 2013). SgK269 is a Lyn substrate, and downregulation of SgK269 in basal breast cancer cells enhanced the conversion of epithelial characteristics from mesenchymal phenotype (Croucher et al. 2013). All these studies point toward the role of Lyn in inducing the invasion of different types of breast cancer.

Lung Cancer

Lyn activation is considered as one of the cellular signaling that influences poor survival rate of lung cancer. In most lung cancer patients, EGFR is constitutively activated. Phosphorylated nuclear translocated EGFR is considered as a key coactivator of different cancer-inducing genes. Downregulation of Lyn inhibited the phosphorylation, nuclear translocation, and tumor-promoting activity of EGFR. The Lyn activation in lung cancer is mediated through PKCßII. The activated Lyn phosphorylates EGFR in association with RACK1 and Cbp/PAG proteins (Sutton et al. 2013). Also enhanced Lyn activity has significant influence on EGFR activation in cetuximab resistance model cells (Lida et al. 2013).

Prostate Cancer

In prostate cancer, two SFKs (Src and Lyn) have been specifically implicated in tumor growth and invasion and metastasis (Park et al. 2008). Lyn expression and activity play a major role in the progression of prostate cancer and development. Lyn stabilizes and enhances the transcriptional activity of androgen receptor in prostate cancer (Zardan et al. 2014). Also Lyn overexpression enhanced AR transcriptional activity both in vitro and in vivo and accelerated castrate-resistant prostate cancer (CRPC) (Zardan et al. 2014). miR-3607 directly represses oncogenic Src family kinases Lyn and Src in prostate cancer (Saini et al. 2014).

Glioblastoma

In primary glioblastomas, Lyn was found to be the predominant active SFK, compared to normal brain or other types of brain tumors (Stettner et al. 2005). Same like other cancers, Lyn kinase activity is significantly elevated in glioblastoma tumors, and its activity promotes the glioblastoma malignant phenotype (Stettner et al. 2005). Lyn enhances the survival of glioblastoma cells by promoting autophagy and proliferation as well as inhibiting cell death, and Lyn promotes the same effects in vivo in xenograft tumors (Liu et al. 2013). Lyn gene expression levels increase with primary glioma tumor grade and inversely correlate with patient survival. Lyn promotes PDGF-mediated migration of glioblastoma cells (Ding et al. 2003).

Colon Cancer

Colon cancer is among the leading causes of cancer death in worldwide. Several SFKs are elevated in colon cancer. CD44, an adhesion and antiapoptotic molecule, is overexpressed in colon cancer. Overexpression of dominant-active Lyn recapitulated chemoresistance via a pathway shown to involve activation of phosphoinositide 3-kinase and Akt (Bates et al. 2001).

Ewing’s Sarcoma

In Ewing’s sarcoma, a poorly differentiated bone/soft tissue cancer is characterized as sharing a common translocation generating an EWS-ETS fusion; Lyn also appears as a potential therapeutic target (Guan et al. 2008). Downregulation of Lyn by RNAi or small molecule inhibitors significantly inhibited the growth and metastatic capacity of these Ewing’s sarcoma lines in vitro and in vivo. It also appeared that the EWS-ETS fusion, a transcription factor, upregulated Lyn gene expression (Guan et al. 2008).

Leukemia and Lymphomas

Lyn kinase plays a significant role in different types of leukemia such as chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), and lymphoma (Donato et al. 2003; Dong and Byrd 2016). A number of reports discovered that the Lyn kinase is a downstream molecule of BCR-Abl fusion protein and contributes significantly toward the action of BCR-Abl-induced leukemogenesis (Warmuth et al. 2003; Wilson et al. 2002). Also Lyn kinase phosphorylates and activates the action BCR-Abl (Meyn et al. 2006). It has been reported that a direct link between Lyn and BCR-Abl signaling pathways as Lyn phosphorylates the Y177 motif of BCR-Abl (Wu et al. 2008), resulting in recruitment of the adaptor Gab2, a principle activator of the PI-3 kinase pathway, both of which are essential for BCR-Abl oncogenesis (Pendergast et al. 1993). Lyn is also involved in other signaling pathways in CML cells, including through BCR-Abl activation of JAK2 that then activates Lyn by preventing SHP-1 from turning off Lyn activity (Samanta et al. 2009). Studies have also confirmed the common activation of Lyn in primary acute myeloid leukemia (AML) and its critical role in maintaining proliferation and antiapoptotic pathways in these cells (Dos Santos et al. 2008). Inhibition of Lyn kinase activity (using genetic and small molecule inhibitors) in AML cell lines substantially decreased cell growth (Roginskaya et al. 1999). Different signaling molecules involved in proliferation and differentiation are associated with Lyn such as mTOR (Dos Santos et al. 2008; Lriyama et al. 2016). These studies indicate that Lyn kinase can be considered as a novel target to AML treatment. Lyn kinase activity was elevated in CLL, B-cell acute lymphoblastic leukemia (B-ALL), and B-cell chronic lymphocytic leukemia (B-CLL) (Contri et al. 2005; Hu et al. 2004). Recent studies suggested reduction in Lyn kinase activity that resulted in a decrease in CLL burden (Nguyen et al. 2016). In B-non-Hodgkin’s lymphomas (B-NHLs), an oncogenic role for Lyn was identified. Lyn inhibitors prevented Lyn-induced phosphorylation of Csk-binding protein (Cbp)/phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG) adaptor (Cbp/PAG), dissociated the signalosome from rafts, and eventually induced death (Tauzin et al. 2008). ETV6-Lyn fusion protein interacts with STAT5 and leads to the direct activation of STAT5 that initiates the induction of myeloproliferative neoplasm (Takeda et al. 2011).

Summary

Several studies revealed that tumor invasion and metastasis are the real drivers of cancer mortality. Inhibiting tumor cell invasion and metastasis may represent a distinct approach to control cancer. Lyn may be a potential target to control the various cancers. By designing potent pharmacological inhibitor(s), targeting Lyn may result in control tumor metastasis, thereby effectively managing several cancer types.

References

  1. Bates RC, Edwards NS, Burns GF, Fisher DE. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res. 2001;61:5275–83.PubMedGoogle Scholar
  2. Boggon TJ, Eck MJ. Structure and regulation of Src family kinases. Oncogene. 2004;23:7918–27.PubMedCrossRefGoogle Scholar
  3. Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, et al. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res. 2010;70:2296–306.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest. 2005;115:369–78.PubMedPubMedCentralCrossRefGoogle Scholar
  5. Croucher DR, Hochgräfe F, Zhang L, Liu L, Lyons RJ, Rickwood D, et al. Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway. Cancer Res. 2013;73:1969–80.PubMedCrossRefGoogle Scholar
  6. Ding Q, Stewart J, Olman MA, Klobe MR, Gladson CL. The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged. J Biol Chem. 2003;278:39882–91.PubMedCrossRefGoogle Scholar
  7. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690–8.PubMedCrossRefGoogle Scholar
  8. Dong S, Byrd JC. A new role for Lyn in the CLL microenvironment. Cancer Cell. 2016;30:511–2.PubMedCrossRefGoogle Scholar
  9. Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Recher C. A critical role for Lyn in acute myeloid leukemia. Blood. 2008;111:2269–79.PubMedCrossRefGoogle Scholar
  10. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro. Breast Cancer Res Treat. 2007;105:319–26.PubMedCrossRefGoogle Scholar
  11. Futami M, Zhu QS, Whichard ZL, Xia L, Ke Y, Neel BG, et al. G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase. Blood. 2011;118:1077–86.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, et al. Targeting Lyn inhibits tumor growth and metastasis in Ewing’s sarcoma. Mol Cancer Ther. 2008;7:1807–16.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Hibbs ML, Stanley E, Maglitto R, Dunn A. Identification of a duplication of the mouse Lyn gene. Gene. 1995;156:175–81.PubMedCrossRefGoogle Scholar
  14. Hu YG, Liu YH, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004;36:453–61.PubMedCrossRefGoogle Scholar
  15. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007;67:2226–38.PubMedCrossRefGoogle Scholar
  16. Huang TH, Huo L, Wang YN, Xia W, Wei Y, Chang SS, et al. Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers. Cancer Cell. 2013;23:796–810.PubMedPubMedCentralCrossRefGoogle Scholar
  17. Ingley E. Functions of the Lyn tyrosine kinase in health and disease. Cell Commun Signal. 2012;10:21.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Ingley E, Payne CJ, Murphy SV, McCarthy DJ, Schnieder JR, Rossjohn J, et al. Src Family Kinases: regulating their activity, levels and identifying new pathways. Acta Biochim Pol. 2007;54:9–10.Google Scholar
  19. Koch C, Anderson D, Moran M, Ellis C, Pawson T. SH2 and SH3 domains: elements that control interactions of cytoplasmic signalling proteins. Science. 1991;252:668–74.PubMedCrossRefGoogle Scholar
  20. Lida M, Brand TM, Campbell DA, Li C, Wheeler DL. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene. 2013;32:759–67.CrossRefGoogle Scholar
  21. Liu WM, Huang P, Kar N, Burgett M, Muller-Greven G, Nowacki AS, et al. Lyn facilitates glioblastoma cell survival under conditions of nutrient deprivation by promoting autophagy. PLoS One. 2013;8:e70804.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Lriyama N, Yuan B, Hatta Y, Takagi N, Takei M. Lyn, a tyrosine kinase closely linked to the differentiation status of primary acute myeloid leukemia blasts, associates with negative regulation of all-trans retinoic acid (ATRA) and dihydroxyvitamin D3 (VD3)-induced HL-60 cells differentiation. Cancer Cell Int. 2016;16:37.CrossRefGoogle Scholar
  23. Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–34.PubMedCrossRefGoogle Scholar
  24. Meyn MA, Wilson MB, Abdi FA, Fahey N, Schiavone AP, Wu J, et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem. 2006;281:30907–16.PubMedCrossRefGoogle Scholar
  25. Nguyen PH, Fedorchenko O, Rosen N, Koch M, Barthel R, Winarski T, et al. LYN kinase in the tumor microenvironment is essential for the progression of chronic lymphocytic leukemia. Cancer Cell. 2016;30:610–22.PubMedCrossRefGoogle Scholar
  26. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008;68:3323–33.PubMedCrossRefGoogle Scholar
  27. Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene. 2004;23:7906–9.PubMedCrossRefGoogle Scholar
  28. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175–85.PubMedCrossRefGoogle Scholar
  29. Pénzes K, Baumann C, Szabadkai I, Orfi L, Kéri G, Ullrich A, et al. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells. Cancer Biol Ther. 2014;15:1571–82.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Resh MD. Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim Biophys Acta. 1999;1451:1–16.PubMedCrossRefGoogle Scholar
  31. Roginskaya V, Zuo S, Caudell E, Nambudiri G, Kraker AJ, Corey SJ. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia. 1999;13:855–61.PubMedCrossRefGoogle Scholar
  32. Saini S, Majid S, Shahryari V, Tabatabai ZL, Arora S, Yamamura S, et al. Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer. Mol Cancer Ther. 2014;13:1952–63.PubMedPubMedCentralCrossRefGoogle Scholar
  33. Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene. 2009;28:1669–81.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, et al. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. J Clin Invest. 2014;124:5490–502.PubMedPubMedCentralCrossRefGoogle Scholar
  35. Selvakumar P, Lakshmikuttyamma A, Shrivastav A, Das SB, Dimmock JR, Sharma RK. Potential role of N-myristoyltransferase in cancer. Prog Lipid Res. 2007;46:1–36.PubMedCrossRefGoogle Scholar
  36. Stettner MR, Wang W, Nabors LB, Bharara S, Flynn DC, Grammer JR, Gillespie GY, Gladson CL. Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res. 2005;65:5535–43.PubMedCrossRefGoogle Scholar
  37. Sun G, Sharma AK, Budde RJ. Autophosphorylation of Src and yes blocks their inactivation by Csk phosphorylation. Oncogene. 1998;17:1587–95.PubMedCrossRefGoogle Scholar
  38. Sun G, Ramdas L, Wang W, Vinci J, McMurray J, Budde RJ. Effect of autophosphorylation on the catalytic and regulatory properties of protein tyrosine kinase Src. Arch Biochem Biophys. 2002;397:11–7.PubMedCrossRefGoogle Scholar
  39. Sutton P, Borgia JA, Bonomi P, Plate JM. Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells. Mol Cancer. 2013;12:76.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Tabariès S, Annis MG, Hsu BE, Tam CE, Savage P, Park M, et al. Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis. Oncotarget. 2015;6:9476–87.PubMedPubMedCentralCrossRefGoogle Scholar
  41. Takeda Y, Nakaseko C, Tanaka H, Takeuchi M, Yui M, Saraya A, et al. Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis. Br J Haematol. 2011;153:589–98.PubMedPubMedCentralCrossRefGoogle Scholar
  42. Tauzin S, Ding H, Khatib K, Ahmad I, Burdevet D, van Echten-Deckert G, et al. Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts. Blood. 2008;111:2310–20.PubMedCrossRefGoogle Scholar
  43. Wang D, Esselman WJ, Cole PA. Substrate conformational restriction and CD45-catalysed dephosphorylation of tail tyrosine-phosphorylated Src protein. J Biol Chem. 2002;277:40428–33.PubMedCrossRefGoogle Scholar
  44. Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW, et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood. 2003;101:664–72.PubMedCrossRefGoogle Scholar
  45. Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene. 2002;21:8075–88.PubMedCrossRefGoogle Scholar
  46. Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib resistant chronic myelogenous leukemia cells. Blood. 2008;111:3821–9.PubMedPubMedCentralCrossRefGoogle Scholar
  47. Yi T, Bolen JB, Ihle JN. Hematopoietic cells express two forms of lyn kinase differing by 21 amino acids in the amino terminus. Mol Cell Biol. 1991;11:2391–8.PubMedPubMedCentralCrossRefGoogle Scholar
  48. Zardan A, Nip KM, Thaper D, Toren P, Vahid S, Beraldi E, et al. Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer. Oncogenesies. 2014;3:e115.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Sai Kundur
    • 3
  • Hung Nguyen
    • 3
  • Lloyd McKee
    • 3
  • Clairissa Cruz
    • 3
  • Ponniah Selvakumar
    • 1
    • 2
    • 3
  • Ashakumary Lakshmikuttyamma
    • 3
  1. 1.Department of Pathology and Laboratory Medicine, College of MedicineUniversity of SaskatchewanSaskatoonCanada
  2. 2.Cancer Research Unit, Saskatchewan Cancer AgencySaskatoonCanada
  3. 3.Department of Pharmaceutical SciencesJefferson College of Pharmacy, Thomas Jefferson UniversityPhiladelphiaUSA